



From Charcot’s descriptions to the current 
understanding of neuropsychiatric symptoms 
in multiple sclerosis
Das descrições de Charcot à compreensão atual dos sintomas neuropsiquiátricos na 
esclerose múltipla
Carlos B. TAUIL1,2, Felipe VON GLEHN3, Raimundo NONATO-RODRIGUES1, Jaqueline R.A.A. GOMES4, 
Carlos O. BRANDÃO3, Leonilda M.B. dos SANTOS3, Leopoldo L. dos SANTOS-NETO1
Like other autoimmune diseases, the pathophysiology of 
multiple sclerosis (MS) involves a complex interaction between 
genetic and environmental factors1. However, psychological 
stressors and states of anxiety and depression also seem to con-
tribute to the onset of clinical and subclinical relapses in MS2. 
Psychiatric symptoms in MS are heterogeneous and asso-
ciated with central nervous system (CNS) abnormalities. 
These symptoms result from the interaction of the individu-
al’s organ and tissue changes influenced by immune system 
activation, not only a “state of the soul”, or solely the result of 
CNS inflammation, but a product of the complex interaction 
between various biological systems3. Neuropsychiatric disor-
ders in MS have been known about since the original clini-
cal pathological description by Charcot in the late nineteenth 
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ABSTRACT
Neuropsychiatric disorders in multiple sclerosis have been known since the original clinicopathological description by Charcot in the late 
nineteenth century. Charcot, in the last decades of his life, became involved in the field of neuropsychiatry. This produced a battle between 
rival schools in the era that still echoes to this day. Charcot’s intuition, including the line of thought of Babinski, one of his most famous 
disciples, was that there was a connection between mood disorders and many of the diseases of the nervous system. Medicine’s concern 
with establishing a relationship between mood disorders and disease stems from the ancient and middle ages with references found in the 
Hippocratic doctrine. However, it was only in the second half of the nineteenth and early twentieth century, with Charcot’s discoveries, that 
this discussion was established in a structured way, laying the foundations of neuropsychiatry.
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RESUMO
Os distúrbios neuropsiquiátricos na esclerose múltipla são conhecidos desde a descrição clínico-patológica original de Charcot no final 
do século XIX. Charcot nas últimas décadas de sua vida se envolveu no campo da neuropsiquiatria. Isso produziu uma batalha de escolas 
rivais na época que ainda ecoa até hoje. A intuição de Charcot, incluindo a linha de pensamento de Babinski, um de seus discípulos mais 
famosos, foi a teoria correta da conexão entre os transtornos do humor e muitas das doenças do sistema nervoso.   A preocupação da 
Medicina em estabelecer uma relação entre transtornos do humor e doenças vem das idades antiga e média, com referências encontradas 
na doutrina hipocrática. No entanto, foi apenas na segunda metade do século XIX e início do século XX que, com as descobertas de Charcot 
essa discussão foi realizada de maneira estruturada, estabelecendo os fundamentos da neuropsiquiatria.
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century4. These symptoms can be divided into two major 
groups: cognitive and behavioral disorders; and affective 
and mood disorders. The second group includes depression, 
fatigue, sleep disorders, bipolar-like disorders, euphoria, 
excessive crying, pathological laughter, and anxiety. 
Previous studies have shown that MS patients pres-
ent with depression significantly more often than other 
patients with chronic diseases, especially young men5. 
However, although these symptoms are common, they are 
often underdiagnosed, causing suffering and worsening 
of the patient’s quality of life. It is estimated, for example, 
that one-third of patients with MS and major depression 
or suicidal ideation receive no treatment for their mood 
disorder6,7 (Figure1)8.
Charcot and Babinski
Murray, in his book on the history of multiple scle-
rosis, described that the earliest systematized and origi-
nal descriptions of MS were well defined by Jean-Martin 
Charcot, a neurologist at Hôpital de Salpêtrière in 1868, as 
“sclérose en plaques”9. The three most reliable indicators 
of multiple sclerosis—intention tremor, nystagmus, and 
scanning speech—became known as the Charcot triad10. 
The analysis in this study at the time, of the first reports 
of patients with MS, pointed to elements of marked relgi-
osity, mysticism, histrionic behavior and even cases of self-
mutilation, already demonstrating an intimate relation-
ship between MS and neuropsychiatry11. Mood and emotion 
disorders in MS were reported by Charcot in his com-
piled Leçons sur les maladies du système nerveux: Faites a 
la Salpêtrière (Lessons on Nervous System Diseases: at the 
Salpêtrière), published in 18684.
This work, a compilation of classes given by Charcot 
at Salpêtrière Hospital, exposed his ideology that was 
undoubtedly influenced by the precepts of Claude Bernard 
(1813-1878). Charcot believed that the description of dis-
eases should be structured beyond Hippocratic clinical 
observation, trying to correlate this with knowledge of 
pathology and experimental medicine12. His studies dem-
onstrated a solid scientific rigor that led to Charcot obtain-
ing the position of Chair for Diseases of the Nervous System 
in 1882, as well as assuring his incontestable leadership of 
several brilliant pupils and their peers. Charcot’s strict but 
unifying personality resulted in a fundamental set of clini-
cal and pathological descriptions that are the basis of mod-
ern neurology13. However, Charcot’s restless investigative 
spirit was not satisfied, and in the last decades of his life, 
he became involved in the complex field of hysteria and 
hypnosis14. This produced a battle between rival schools in 
the era that echoes to this day. Charcot’s intuition, includ-
ing the line of thought of Babinski, one of his most famous 
disciples, led to his hypothesis of a bidirectional connection 
between psychiatric or mood disorders and many of the dis-
eases of the nervous system14.
Studies beyond the twentieth century 
In 1883, Julius Wagner-Jauregg described the case of 
a woman with psychotic hallucinations, who had a high 
fever due to a skin infection, but when the infectious pro-
cess resolved, the psychotic symptoms disappeared15. 
Wagner-Jauregg spent the next decades of his career trying to 
replicate what he had observed and, by 1917, had some suc-
cess in treating patients who had psychosis due to tertiary 
syphilis with blood from soldiers with malaria (Figure 216). 
Figure 1. Charcot teaching about hysteria in Salpêtrière Hospital, Paris8.
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This treatment, known as malariotherapy, was used in thou-
sands of patients between the 1920s and 1930s and accorded 
Wagner-Jauregg the Nobel Prize in Medicine in 192715.
Among others, there was an original description of MS 
associated with depression made by Wilhelm Nero Pilate 
Barbellion, the pseudonym of Bruce Frederick Cummings, 
who reported on his life with a chronic neurological disease 
in his Journal of a Disappointed Man14.
The first series of cases describing the association 
between mood disorders and MS was published as a struc-
tured paper similar to contemporaneous ones in 1926. In this 
study, Cottrell and Wilson reported a case series analyzing 
the relationship between affective symptoms and MS17.
In the early 1990s, a relationship of the immune system 
with depression, as proposed by Smith18, and Kwidzinski and 
Bechmann19, suggested that proinflammatory cytokines, 
such as IL-1, activate the corticotropin-releasing factor of 
the hypothalamus, inducing hyperactivation of the hypotha-
lamic-pituitary-adrenal axis and the symptoms of depression. 
Final considerations
In recent decades, the relationship between neuropsy-
chiatry and neuroimmunology has intensified as scientific 
findings have revealed consistent evidence of the influ-
ence of mood disorders on diseases in general, and on MS 
in particular20.
Medicine’s concern with establishing a relationship 
between temperament, personality, mood disorders, and dis-
ease stems from the ancient and middle ages, with references 
found in the texts by Hippocrates and Galen12. However, it was 
only in the second half of the nineteenth and early twentieth 
century, with Charcot’s pioneering studies, that this discus-
sion was established in a structured way, laying the founda-
tions for neuropsychiatry14. In the period between the world 
wars, clinical observations of the relationship between the 
immunological reaction and its influence on psychiatric dis-
eases were reported by Wagner-Jauregg, and malariotherapy 
was developed15. Cottrell and Wilson published one of the 
first papers demonstrating the epidemiological relationship 
between mood disorders and MS17.
With our current knowledge of neuroimmunology, espe-
cially concerning studies of MS and autoimmune encepha-
litis, we can find scientific confirmation of the epidemio-
logical and molecular aspects of the intimate relationship 
between mood disorders and behavior, and immune system 
activity explaining, in a consistent and scientifically rigor-
ous manner, the hypotheses made over a century ago by 
Charcot and his disciples21,22.
References
1. Mancuso R, Hernis A, Agostini S, Rovaris M, Caputo D, Fuchs D, 
et al. Indoleamine 2,3 dioxygenase (IDO) expression and activity 
in relapsing-remitting multiple sclerosis. PLoS One. 2015 
Jun;10(6):e0130715. https://doi.org/10.1371/journal.pone.0130715  
2. Rossi S, Studer V, Motta C, Polidoro S, Perugini J, Macchiarulo 
G, et al. Neuroinflammation drives anxiety and depression 
in relapsing-remitting multiple sclerosis. Neurology. 2017 
Sep;89(13):1338-47. Available from: http://ovidsp.ovid.com/ovidweb.
cgihttps://doi.org/10.1212/WNL.0000000000004411  
3. Boeira MV, Berni GA, Passos IC, Kauer-Sant’Anna M, 
Kapczinski F. Virginia Woolf, neuroprogression, and bipolar 
disorder. Br J Psychiatry. 2017 Jan-Mar;39(1):69-71. 
https://doi.org/10.1590/1516-4446-2016-1962
4. Charcot JM. Leçons sur les maladies du système nerveux: faites a la 
Salpêtrière. Paris;1877. Vol  II: Sclerose en plaques,  293-294. 
5. Simpson S Jr, Tan H, Otahal P, Taylor B, Ponsonby AL, Lucas RM, 
et al. Anxiety, depression and fatigue at 5-year review following 
CNS demyelination. Acta Neurol Scand. 2016 Dec;134(6):403-13. 
https://doi.org/10.1111/ane.12554
6. Fragoso YD, Frota ER, Lopes JS, Noal JS, Giacomo MC,  
Gomes S, et al. Severe depression, suicide attempts,  
and ideation during the use of interferon beta by  
patients with multiple sclerosis [serial online]. 
Clin Neuropharmacol. 2010 Nov-Dec;33(6):312-6. 
https://doi.org/10.1097/WNF.0b013e3181f8d513
7. World Health Organization – WHO. Projections of mortality 
and causes of death, 2015 and 2030. Geneva: World Health 
Organization; 2013.
8. Broillet PA. Painting. Une leçon clinique sur l’hysterie a la 
Salpêtrière: Image mod. Scale. 1887 [cited  2018 June 22] 
Availablefrom:https://pt.wikipedia.org/wiki/Charcot_La Salpêtrière
9. Murray TJ. Multiple sclerosis: the history of a disease. New York: 
Demos Medical; 2005. Chapter 4: The steps toward a discovery: the 
early medical reports; p. 61-95.
10. Murray TJ. Multiple sclerosis: the history of a disease. New York: 
Demos Medical; 2005.Chapter 5: The building blocks of discovery; 
p. 95-103.
11. Murray TJ. Multiple sclerosis: the history of a disease. New York: 
Demos Medical; 2005.Chapter 6: The Contribuition of J.M.Charcot – 
1868; p.103-39.
12. Finger S. Origins of Neuroscience : a history of explorations into 
brain function. Oxford: Oxford University Press; 1994. 
Figure 2. Wagner-Jauregg and the theory of malariotherapy16.
524 Arq Neuropsiquiatr 2019;77(7):521-524
13. Lyons AS, Petrucelli RJ. Medicine an illustrated history. New York: 
Harry N. Abrams.; 1987.
14. Bogousslavsky J. Following Charcot: a forgotten history of neurology 
and psychiatry. Basel: Karger; 2011. (Frontiers of Neurology and 
Neuroscience; Vol. 29). 
15. Wetsman N. Inflammatory illness: why the next wave of 
antidepressants may target the immune system. Nat Med. 2017 
Sep;23(9):1009-11. https://doi.org/10.1038/nm0917-1009
16. Vogel, G. Malaria as Lifesaving Therapy. Science. 2013 
Nov;342(6159):686. https://doi.org/10.1126/science.342.6159.686
17. Cottrell SS, Wilson SA. The affective symptomatology of 
dissaminated sclerosis: a study of 100 cases. J Neurol Psychopathol. 
1926 Jul;7(25):1-30. https://doi.org/10.1136/jnnp.s1-7.25.1
18. Smith RS. The macrophage theory of depression. 
Med Hypotheses. 1991 Aug;35(4):298-306. 
https://doi.org/10.1016/0306-9877(91)90272-Z
19. Kwidzinski E, Bechmann I. IDO expression in the brain: a 
double-edged sword. J Mol Med (Berl). 2007 Dec;85(12):1351-9. 
https://doi.org/10.1007/s00109-007-0229-7
20. Murphy R, O’Donoghue S, Counihan T, McDonald C,  
Calabresi PA, Ahmed M A S, et al. Neuropsychiatric  
syndromes of multiple sclerosis. J Neurol Neurosurg  
Psychiatry. 2017 Aug;88(8):697-708. 
https://doi.org/10.1136/jnnp-2016-315367
21. Dalmau J, Graus F. Antibody-Mediated Encephalitis.  
N Engl J Med. 2018 Mar;378(9):840-51. 
https://doi.org/10.1056/NEJMra1708712
22. McKay KA, Tremlett H, Fisk JD, Zhang T, Patten SB, 
Kastrukoff L, et al.; CIHR Team in the Epidemiology and 
Impact of Comorbidity on Multiple Sclerosis. Psychiatric 
comorbidity is associated with disability progression in 
multiple sclerosis. Neurology. 2018 Apr;90(15):e1316-23. 
https://doi.org/10.1212/WNL.0000000000005302
